Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks

Stock Research Monitor: AKRX, COLL, and LPCN

LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want a free Stock Review on HZNP sign up now at www.wallstequities.com/registration. WallStEquities.com features the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. The market for generic drugs is based on the premise that patented drugs come with a lifespan of 20 years, which begins from the phase of clinical trials. In this morning’s lineup are these four stocks: Akorn Inc. (NASDAQ: AKRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), Horizon Pharma PLC (NASDAQ: HZNP), and Lipocine Inc. (NASDAQ: LPCN). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Akorn

On Thursday, shares in Lake Forest, Illinois headquartered Akorn Inc. recorded a trading volume of 3.04 million shares. The stock ended at $13.61, jumping 6.25% from the last trading session. The Company’s shares are trading below their 50-day moving average by 20.97%. Furthermore, shares of Akorn, which develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter consumer health products, and animal health pharmaceuticals in the US and internationally, have a Relative Strength Index (RSI) of 40.50.

On April 23rd, 2018, Akorn filed a complaint in Delaware Chancery Court asking that Fresenius Kabi AG be required to fulfill its obligations under the definitive merger agreement. The transaction was announced on April 24th, 2017, after the boards of directors of both companies approved the sale of Akorn to Fresenius Kabi for $34.00 a share in cash. Akorn’s shareholders voted overwhelmingly to approve the transaction on July 19th, 2017. Get the full research report on AKRX for free by clicking below at:

www.wallstequities.com/registration/?symbol=AKRX

Collegium Pharmaceutical

Canton, Massachusetts headquartered Collegium Pharmaceutical Inc.’s stock finished yesterday’s session 7.73% higher at $25.79. A total volume of 1.29 million shares was traded, which was above their three months average volume of 505,560 shares. The Company’s shares have gained 13.91% in the last month, 22.81% over the previous three months, and 208.49% over the past year. The stock is trading above its 50-day and 200-day moving averages by 4.18% and 46.49%, respectively. Furthermore, shares of Collegium Pharma, which develops and commercializes various products for patients suffering from pain, have an RSI of 57.99.

On May 09th, 2018, Collegium Pharma reported its financial results for Q1 2018. Net product revenues for Q1 2018 were $63.7 million; net loss was $18.7 million; R&D expenses were $2.3 million; and SG&A expenses were $31.6 million. The Company had cash and cash equivalents of $128.2 million, as of March 31st, 2018. The free technical report on COLL can be accessed at:

www.wallstequities.com/registration/?symbol=COLL

Horizon Pharma

At the close of trading on Thursday, shares in Dublin, Ireland headquartered Horizon Pharma PLC saw a slight decline of 0.58%, ending the day at $13.73. The stock recorded a trading volume of 3.20 million shares, which was above its three months average volume of 1.88 million shares. The Company’s shares have advanced 1.63% in the previous three months and 42.35% over the past year. The stock is trading 1.38% below its 200-day moving average. Moreover, shares of Horizon Pharma, which focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the US and internationally, have an RSI of 44.93.

On May 01st, 2018, Horizon Pharma announced that it will participate in the UBS Global Healthcare Conference on May 22nd, 2018 at 9:30 a.m. ET in New York. The presentation will be webcast live and may be accessed on the Company’s investors website. Sign up for free on Wall St. Equities and claim the latest report on HZNP at:

www.wallstequities.com/registration/?symbol=HZNP

Lipocine

Salt Lake City, Utah headquartered Lipocine Inc.’s shares ended the day 7.02% lower at $1.06. A total volume of 538,025 shares was traded, which was above their three months average volume of 493,550 shares. The stock is trading 32.87% below its 50-day moving average. Additionally, shares of Lipocine, which focuses on the development of pharmaceutical products in the area of men’s and women’s health, have an RSI of 31.09.

On May 07th, 2018, Lipocine announced its results for Q1 ended March 31st, 2018. Net loss for Q1 2018 was $2.7 million; license revenues were $428,000; R&D expenses were $1.4 million; and G&A expenses were $1.7 million. As of March 31st, 2018, the Company had cash, cash equivalents, and marketable securities of $27.8 million. See the free research coverage on LPCN at:

www.wallstequities.com/registration/?symbol=LPCN

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 499336